A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
about
Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): Report of 5 cases and review of the literature.Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour groupPancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.Distinctive pathological and clinical features of lung carcinoids with high proliferation index.Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas.Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.Classification of pulmonary neuroendocrine tumors: new insights.Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor.Cyto-histology in NET: what is necessary today and what is the future?Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.Phenotypic variation of an ALK-positive large-cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors.Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift.The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.G3 GEP NENs category: are basic and clinical investigations well integrated?Molecular characterisation of metastatic pancreatic neuroendocrine tumours (PNETs) using whole genome and transcriptome sequencing.Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study.The Evolution of Neuroendocrine Tumor Treatment reflected by ENETS Guidelines.[Neuroendocrine neoplasms of the head and neck].Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology.Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).An Advanced well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroupENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin AnaloguesProfiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 ClassificationCell-Free DNA From Metastatic Pancreatic Neuroendocrine Tumor Patients Contains Tumor-Specific Mutations and Copy Number Variations
P2860
Q30238552-5DEDF863-6C5D-4488-B9F3-7A42FFA3132AQ33606047-9797BC43-8263-403E-96F5-498C29187D01Q37629658-366DF25A-D872-4209-9E90-82399DED0BA8Q37631597-D02EB96F-F402-44C8-8CF2-7DBDF0905006Q38718054-19BC1F64-7B23-40D4-A5A9-7A3E44287893Q38764884-07C7586C-2ACC-4680-968A-B67FC8E60C99Q38769603-BD27D793-35A3-4F96-8C22-073840ECCB53Q42379480-F7BEAA1C-63FA-4AD8-AFA9-EB448734DB82Q45140096-7032B744-1602-440C-ACA4-6D7FBF80C664Q46513952-D920CC17-7311-43C4-95CF-87A6744E1CFCQ47218406-498E2EB5-5185-4C25-A72B-66FD8121935CQ47358369-316232ED-143A-4E26-B46E-32E5A5930C0CQ47594456-E64B9558-8A30-4865-86AD-9F668F469782Q47734687-3B688C61-FF4D-46E3-9DA5-1391D886A173Q47890492-0300926D-5454-4C3C-BAC8-36724071CEB1Q47965331-07188C9B-D01E-4CB8-B1D0-61A01427F28CQ48088751-9B12DD44-5B08-4310-BDBF-6CC5DB0C84E2Q48099048-6FD45FEA-F8D0-426C-9501-032F8A15E5D2Q48120139-1D469BA3-86AF-47F2-9DB0-B84D96152D26Q48221145-F782B575-6565-4B31-9E1F-DD188434B781Q48295398-EBC39D34-B0D7-4FEE-A95E-4D52DADA4B8FQ48362953-38CB7199-B0A2-42EC-9CBA-AD37A0F15314Q48380432-56E58520-E38D-4377-B1C0-15C8B6183824Q49732322-E11E6118-78BD-4406-8493-A4D0DE9F59CDQ49928150-BF02746D-3CB6-4751-A448-9327FB8ED774Q50103017-E9B956A1-A78E-4B74-8A8A-B61847115E58Q50128151-4D2ADF64-7223-4519-92AF-692D58DF7F38Q50143284-61A90379-D110-4845-BE6A-FE5D75378030Q50355400-B543468F-44FD-49FB-B4F5-0412AA2F04E8Q52670584-F5111943-F8BF-41AE-8863-FFD76B3606FBQ52680744-E938B269-9710-4F27-82E4-1427C41394CFQ52744623-9E6C674E-34DD-49B2-B2B1-4CBE1BB8F50CQ55287682-5AC3B528-F095-4545-AB25-37B8566237CDQ57471936-18C93560-8298-4139-A5CB-A5B49F829C1BQ57990732-B9E9A1A6-D706-4838-BBCF-68C493F936CEQ58769285-913919E1-E2D0-4E5B-A34A-DF931A982A51Q59137752-5E6796B1-3EA8-4D1B-92B4-84CB2DF411A6
P2860
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A Practical Approach to the Cl ...... noma (PD-NEC) of the Pancreas.
@en
type
label
A Practical Approach to the Cl ...... noma (PD-NEC) of the Pancreas.
@en
prefLabel
A Practical Approach to the Cl ...... noma (PD-NEC) of the Pancreas.
@en
P2093
P2860
P1476
A Practical Approach to the Cl ...... noma (PD-NEC) of the Pancreas.
@en
P2093
David S Klimstra
Jillian J Sue
Laura H Tang
P2860
P304
P356
10.1097/PAS.0000000000000662
P407
P50
P577
2016-06-01T00:00:00Z